IPO registrations (S-1, F-1) · Registrants
Skye Bioscience, Inc.
- SEC CIK
- 1516551 · filings on EDGAR ↗
- Former names
- Emerald Bioscience, Inc. (2019–2021); Nemus Bioscience, Inc. (2014–2019); LOAD GUARD LOGISTICS, INC. (2012–2014); LOAD GUARD TRANSPORTATION, INC. (2011–2012)
- Registration
- Form S-1, first filed 2013-01-30, last 2024-04-04; 10 initial registrations, 11 amendments
- Outcome
- Final prospectus filed 2019-11-13; declared effective 2013-06-12
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- NV
- Business address
- 11250 EL CAMINO REAL, SUITE 100, San Diego, CA 92130
- EIN
- 45-0692882
- Ticker
- SKYE (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Skye Bioscience, Inc. on the corporate pages
Offering terms
- Final price
- $0.06 per share (424B4 filed 2020-08-03)
- Listing
- OTCQB under the symbol EMBI
- Lead underwriters
- H.C. Wainwright
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: SKYE BIOSCIENCE INC. EXACT (EIN (EXACT))
- Form D issuer: Skye Bioscience, Inc. EXACT (CIK (EXACT))
- SEC filer: Emerald Bioscience, Inc. EXACT (CIK (EXACT))
- Person page: John D Diekman Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 43
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-01-30 | S-1 | S-1 (registration) | LOAD GUARD LOGISTICS, INC. | 0001557240-13-000010 ↗ |
| 2013-03-22 | S-1/A | S-1/A (amendment) | LOAD GUARD LOGISTICS, INC. | 0001557240-13-000048 ↗ |
| 2013-04-26 | S-1/A | S-1/A (amendment) | LOAD GUARD LOGISTICS, INC. | 0001557240-13-000089 ↗ |
| 2013-05-13 | S-1/A | S-1/A (amendment) | LOAD GUARD LOGISTICS, INC. | 0001557240-13-000107 ↗ |
| 2013-05-29 | S-1/A | S-1/A (amendment) | LOAD GUARD LOGISTICS, INC. | 0001557240-13-000129 ↗ |
| 2013-06-10 | S-1/A | S-1/A (amendment) | LOAD GUARD LOGISTICS, INC. | 0001557240-13-000151 ↗ |
| 2013-06-12 | EFFECT | EFFECT (declared effective) | LOAD GUARD LOGISTICS, INC. | 9999999995-13-001773 ↗ |
| 2015-09-17 | S-1 | S-1 (registration) | Nemus Bioscience, Inc. | 0001640334-15-000166 ↗ |
| 2015-10-28 | S-1/A | S-1/A (amendment) | Nemus Bioscience, Inc. | 0001640334-15-000251 ↗ |
| 2015-11-17 | S-1/A | S-1/A (amendment) | Nemus Bioscience, Inc. | 0001640334-15-000348 ↗ |
| 2015-11-20 | EFFECT | EFFECT (declared effective) | Nemus Bioscience, Inc. | 9999999995-15-003103 ↗ |
| 2016-04-25 | EFFECT | EFFECT (declared effective) | Nemus Bioscience, Inc. | 9999999995-16-004315 ↗ |
| 2016-11-22 | S-1 | S-1 (registration) | Nemus Bioscience, Inc. | 0001640334-16-002109 ↗ |
| 2016-12-05 | EFFECT | EFFECT (declared effective) | Nemus Bioscience, Inc. | 9999999995-16-006379 ↗ |
| 2017-01-20 | S-1 | S-1 (registration) | Nemus Bioscience, Inc. | 0001640334-17-000146 ↗ |
| 2017-02-08 | EFFECT | EFFECT (declared effective) | Nemus Bioscience, Inc. | 9999999995-17-000328 ↗ |
| 2017-03-13 | S-1 | S-1 (registration) | Nemus Bioscience, Inc. | 0001640334-17-000465 ↗ |
| 2017-03-23 | EFFECT | EFFECT (declared effective) | Nemus Bioscience, Inc. | 9999999995-17-000646 ↗ |
| 2017-11-22 | S-1 | S-1 (registration) | Nemus Bioscience, Inc. | 0001640334-17-002507 ↗ |
| 2017-12-04 | EFFECT | EFFECT (declared effective) | Nemus Bioscience, Inc. | 9999999995-17-003138 ↗ |
| 2018-03-23 | S-1 | S-1 (registration) | Nemus Bioscience, Inc. | 0001640334-18-000530 ↗ |
| 2018-04-13 | S-1/A | S-1/A (amendment) | Nemus Bioscience, Inc. | 0001640334-18-000724 ↗ |
| 2018-04-16 | EFFECT | EFFECT (declared effective) | Nemus Bioscience, Inc. | 9999999995-18-000828 ↗ |
| 2019-06-04 | S-1 | S-1 (registration) | Emerald Bioscience, Inc. | 0001640334-19-001037 ↗ |
| 2019-10-23 | S-1/A | S-1/A (amendment) | Emerald Bioscience, Inc. | 0001640334-19-002094 ↗ |
| 2019-10-28 | EFFECT | EFFECT (declared effective) | Emerald Bioscience, Inc. | 9999999995-19-002407 ↗ |
| 2019-11-13 | S-1MEF | S-1MEF (added securities) | Emerald Bioscience, Inc. | 0001640334-19-002256 ↗ |
| 2019-11-13 | 424B4 | 424B4 (final prospectus) | Emerald Bioscience, Inc. | 0001640334-19-002259 ↗ |
| 2019-12-31 | EFFECT | EFFECT (declared effective) | Emerald Bioscience, Inc. | 9999999995-20-000003 ↗ |
| 2020-02-13 | EFFECT | EFFECT (declared effective) | Emerald Bioscience, Inc. | 9999999995-20-000343 ↗ |
| 2020-03-17 | EFFECT | EFFECT (declared effective) | Emerald Bioscience, Inc. | 9999999995-20-000578 ↗ |
| 2020-07-13 | S-1 | S-1 (registration) | Emerald Bioscience, Inc. | 0001640334-20-001743 ↗ |
| 2020-07-28 | S-1/A | S-1/A (amendment) | Emerald Bioscience, Inc. | 0001640334-20-001865 ↗ |
| 2020-07-31 | S-1MEF | S-1MEF (added securities) | Emerald Bioscience, Inc. | 0001640334-20-001921 ↗ |
| 2020-07-31 | EFFECT | EFFECT (declared effective) | Emerald Bioscience, Inc. | 9999999995-20-001992 ↗ |
| 2020-08-03 | 424B4 | 424B4 (final prospectus) | Emerald Bioscience, Inc. | 0001640334-20-001952 ↗ |
| 2021-08-09 | EFFECT | EFFECT (declared effective) | Skye Bioscience, Inc. | 9999999995-21-003111 ↗ |
| 2024-03-27 | S-1 | S-1 (registration) | Skye Bioscience, Inc. | 0001628280-24-013372 ↗ |
| 2024-04-04 | S-1/A | S-1/A (amendment) | Skye Bioscience, Inc. | 0001628280-24-014904 ↗ |
| 2024-04-10 | EFFECT | EFFECT (declared effective) | Skye Bioscience, Inc. | 9999999995-24-000923 ↗ |
| 2024-04-26 | EFFECT | EFFECT (declared effective) | Skye Bioscience, Inc. | 9999999995-24-001154 ↗ |
| 2024-05-17 | EFFECT | EFFECT (declared effective) | Skye Bioscience, Inc. | 9999999995-24-001575 ↗ |
| 2024-05-17 | EFFECT | EFFECT (declared effective) | Skye Bioscience, Inc. | 9999999995-24-001576 ↗ |
Prospectus pages read 5
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2018-04-13 | S-1/A | registration statement | $0.10 | 32,500,000 | $3,250,000 | OTCQB NMUS | 0 | primary document; price line, shares headline, proceeds computed | document ↗ | |
| 2019-06-04 | S-1 | registration statement | - | - | OTCQB EMBI | 0 | primary document; no terms found | document ↗ | ||
| 2019-10-23 | S-1/A | registration statement | - | - | OTCQB EMBI | 0 | primary document; no terms found | document ↗ | ||
| 2019-11-13 | 424B4 | final prospectus | - | - | OTCQB EMBI | 0 | primary document; no terms found | document ↗ | ||
| 2020-08-03 | 424B4 | final prospectus | $0.06 | - | - | OTCQB EMBI | 1 | primary document; price sentence, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| MENDEZ FRANCISCO JAVIER | Director,Officer,TenPercentOwner; Other | Secretary | 3 | 2014 | |
| Mendez Yosbani | Director,Officer,TenPercentOwner; Other | CEO, CFO, Treasurer | 2 | 2014 | |
| Berecz Elizabeth | Officer | Chief Financial Officer | 4 | 2014–2018 | |
| Hollister John B | Director,Officer | Chief Executive Officer | 2 | 2014 | |
| Lapham Reg Alexander | TenPercentOwner | 2 | 2014–2017 | ||
| LYKOS COSMAS N | Director,Officer,TenPercentOwner | Chairman; Chairman of the Board | 4 | 2014–2018 | |
| McLaughlin Gerald W. | Director | 5 | 2014–2015 | ||
| Murphy Brian Stuart | Director,Officer; Officer | CEO, Chief Medical Officer; Chief Medical Officer | 4 | 2014–2018 | |
| Ladin Brian D | TenPercentOwner | 2 | 2014–2015 | ||
| GEORGE THOMAS | Director | 3 | 2015 | ||
| Squires Richard D. | TenPercentOwner | 1 | 2015 | ||
| INGRAM DOUGLAS S | Director,Officer | Vice Chairman | 4 | 2015 | |
| DHILLON PUNIT | Director; Director,Officer | CEO; Chief Executive Officer | 17 | 2018–2026 | |
| HEPPELL JAMES L | Director | 4 | 2018–2021 | ||
| Emerald Health Sciences Inc. | TenPercentOwner | 13 | 2018–2023 | ||
| Cesario Douglas A | Officer | CFO and Secretary | 2 | 2018 | |
| DHILLON AVTAR S | Director | 2 | 2018 | ||
| KIM DENNIS D | Officer | Chief Medical Officer | 3 | 2019–2020 | |
| Traistaru Elena | Officer | CFO and Secretary; Interim CFO and Secretary | 2 | 2020 | |
| DALESANDRO MARGARET | Director | 7 | 2020–2024 | ||
| Janney Richard | Officer | Principal Accounting Officer | 1 | 2020 | |
| TYLE PRAVEEN | Director | 8 | 2021–2024 | ||
| ARSENAULT KAITLYN | Officer | Chief Financial Officer | 12 | 2021–2026 | |
| Ward Keith Wayne | Director | 6 | 2021–2024 | ||
| Rai Sukhwinder Singh | Director | 4 | 2022–2023 | ||
| Charych Deborah H. | Director | 10 | 2023–2026 | ||
| Grayson Paul A. | Director | 9 | 2023–2026 | ||
| Schwab Andrew J. | Director; Director,TenPercentOwner | 16 | 2023–2026 | ||
| 5AM CO-INVESTORS II LP | TenPercentOwner | 8 | 2023–2026 | ||
| 5AM Partners II, LLC | TenPercentOwner | 8 | 2023–2026 | ||
| 5AM Partners VII, LLC | TenPercentOwner | 8 | 2023–2026 | ||
| 5AM Ventures II LP | TenPercentOwner | 8 | 2023–2026 | ||
| 5AM Ventures VII, L.P. | TenPercentOwner | 8 | 2023–2026 | ||
| DIEKMAN JOHN D | TenPercentOwner | 8 | 2023–2026 | person page Fuzzy | |
| PARMAR KUSH | TenPercentOwner | 8 | 2023–2026 | ||
| ROCKLAGE SCOTT M | TenPercentOwner | 8 | 2023–2026 | ||
| Versant Side Fund III, L.P. | TenPercentOwner | 1 | 2023 | ||
| Versant Venture Capital III, L.P. | TenPercentOwner | 1 | 2023 | ||
| Versant Ventures III, LLC | TenPercentOwner | 1 | 2023 | ||
| Diep Tuan Tu | Officer | Chief Development Officer; Chief Operating Officer | 8 | 2024–2026 | |
| Jenkins Annalisa | Director | 6 | 2024–2026 | ||
| Smith Karen L. | Director | 6 | 2024–2026 | ||
| Arora Puneet S. | Officer | Chief Medical Officer | 4 | 2024–2026 | |
| Twitty Christopher | Officer | Chief Scientific Officer | 3 | 2025–2026 | |
| Sharp John P | Officer | Chief Financial Officer | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2024-03-27 | Skye Bioscience, Inc. | Biotechnology | $40,000,000 | $40,000,000 | 13 | 1 |
| 2024-02-12 | Skye Bioscience, Inc. | Biotechnology | $49,991,010 | $49,991,010 | 11 | 1 |
| 2023-08-29 | Skye Bioscience, Inc. | Biotechnology | $62,254,435 | $62,254,435 | 12 | 1 |
| 2018-11-15 | Nemus Bioscience, Inc. | Pharmaceuticals | $32,500,000 | $2,000,000 | 1 | 1 |
| 2018-01-25 | Nemus Bioscience, Inc. | Pharmaceuticals | $8,570,000 | $4,150,000 | 2 | 2 |
| 2017-11-14 | Nemus Bioscience, Inc. | Pharmaceuticals | $2,000,000 | $2,000,000 | 2 | 1 |
| 2017-01-13 | Nemus Bioscience, Inc. | Pharmaceuticals | $1,500,000 | $1,200,000 | 5 | 1 |
| 2016-11-03 | Nemus Bioscience, Inc. | Pharmaceuticals | $500,000 | $500,000 | 1 | 1 |
| 2015-08-27 | Nemus Bioscience, Inc. | Pharmaceuticals | $5,000,000 | $5,000,000 | 15 | 1 |
| 2015-04-15 | Nemus Bioscience, Inc. | Pharmaceuticals | $2,500,000 | $625,000 | 5 | 1 |
| 2015-01-09 | Nemus Bioscience, Inc. | Pharmaceuticals | $724,989 | $724,989 | 7 | 1 |
| 2014-11-13 | Nemus Bioscience, Inc. | Pharmaceuticals | Indefinite | $0 | 43 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | SKYE BIOSCIENCE INC. | CA | Form 5500 (employee benefit plans) | name and state |
| Form D issuer | Skye Bioscience, Inc. | CA | Form D private offerings | CIK (EXACT) |
| SEC filer | Skye Bioscience, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Skye Bioscience, Inc. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | SKYE BIOSCIENCE INC. | EIN (EXACT) | ||
| Person page | John D Diekman | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, CA first:
- CONNETICS CORP CA
- SIBIA NEUROSCIENCES INC CA
- MEDIVATION, INC. CA
- IMMUSOL INC CA
- DYNAVAX TECHNOLOGIES CORP CA
- RIGEL PHARMACEUTICALS INC CA
- Diadexus, Inc. CA
- CymaBay Therapeutics, Inc. CA
- CRESCENDO PHARMACEUTICALS CORP CA
- SPIROS DEVELOPMENT CORP II INC CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health